Basit öğe kaydını göster

Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

dc.contributor.authorKalincik, T.
dc.contributor.authorJokubaitis, V.
dc.contributor.authorSpelman, T.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E.
dc.contributor.authorTrojano, M.
dc.contributor.authorBarnett, M.
dc.date.accessioned2020-06-21T13:18:14Z
dc.date.available2020-06-21T13:18:14Z
dc.date.issued2017
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12229
dc.description7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEen_US
dc.descriptionLugaresi, Alessandra/0000-0003-2902-5589; McCombe, Pamela/0000-0003-2704-8517; Ferraro, Diana/0000-0003-4818-3806en_US
dc.descriptionWOS: 000413730203308en_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogenBiogen; MerckMerck & Company; Teva; NovartisNovartis; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; Actelion; Receptos; GenzymeGenzyme Corporation; Biogen-IdecBiogen; BayerBayer AG; SanofiSanofi-Aventis; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); Teva Canada Innovation; Genzyme SanofiGenzyme Corporation; EMD; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Teva-Neuroscience; Canadian Multiple sclerosis society; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Bayer-ScheringBayer AG; Bayer ScheringBayer AGen_US
dc.description.sponsorshipDana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012).; Eva Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Merck, Novartis, Receptos, Genzyme and Teva, as well as support for research activities from Biogen, and Merck.; Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis.; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Alexandre Prat did not declare any competing interests.; Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD. He has also received a research grant from Canadian Institutes of Health Research.; Pierre Grammond is a Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Murat Terzi received travel grants from Merck, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.; Suzanne Hodgkinson received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleCladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosisen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume23en_US
dc.identifier.startpage596en_US
dc.identifier.endpage597en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster